quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:33:41·108d
INSIDERFiling
Compass Therapeutics Inc. logo

CEO Schuetz Thomas J. was granted 250,000 shares, increasing direct ownership by 4% to 6,686,800 units (SEC Form 4)

CMPX· Compass Therapeutics Inc.
Health Care
Original source

Companies

  • CMPX
    Compass Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Feb 13UpdateCraig Hallum$15.00
  • Jan 5UpdateWilliam Blair-
  • Dec 3UpdateCitizens JMP$10.00
  • Dec 3UpdateCanaccord Genuity$10.00
  • Dec 3UpdateCantor Fitzgerald-
  • Jul 1UpdateRaymond James$9.00

Related

  • SEC43d
    SEC Form S-8 filed by Compass Therapeutics Inc.
  • SEC50d
    SEC Form 10-K filed by Compass Therapeutics Inc.
  • SEC50d
    Compass Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR50d
    Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
  • PR52d
    Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
  • SEC69d
    Amendment: SEC Form SCHEDULE 13G/A filed by Compass Therapeutics Inc.
  • ANALYST70d
    Craig Hallum initiated coverage on Compass Therapeutics with a new price target
  • INSIDER73d
    CHIEF EXECUTIVE OFFICER Schuetz Thomas J. covered exercise/tax liability with 36,687 shares, decreasing direct ownership by 0.55% to 6,603,336 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022